Odyssey Therapeutics, Inc.
ODTXHealthcare|Biotechnology|US
$19.23
+0.35 (+1.85%)
Tangible Book / Share
$7.53
Cash / Share
$6.79
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06850727 Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis (UC), UC - Ulcerative Colitis | P2 | Recruiting | 57 | RCT, Double-blind | OD-07656, Vedolizumab |
| NCT07900607 The Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants | Health Volunteers | P1 | Recruiting | 8 | Open-label | [14C]OD-001 |
| NCT06206811 Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants | Inflammatory Bowel Diseases, Blau Syndrome | P1 | Completed | 101 | RCT, Single-blind | OD-07656 |
| NCT05033444 A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers | Traumatic Brain Injury (TBI) | P1 | Completed | 40 | RCT, Double-blind | PRV-002, Placebo |
| NCT05120856 AAT-App Outpatient Trial | Alcohol Use Disorder (AUD) | N/A | Completed | 82 | RCT, Double-blind | — |